Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis


Autoria(s): OLIVEIRA, Joana Tavares de; MATOS, Augusto J. F. de; GOMES, Joana; VILANOVA, Manuel; HESPANHOL, Venceslau; MANNINEN, Aki; RUTTEMAN, Gerard; CHAMMAS, Roger; GAERTNER, Fatima; BERNARDES, Emerson Soares
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2010

Resumo

Galectin-3 is a glycan-binding protein that mediates cell-cell and/or cell-extracellular matrix (ECM) interactions. Although galectin-3 is implicated in the progression of various types of cancers, the mechanisms by which galectin-3 enhances metastasis remain unclear. In order to elucidate the role of galectin-3 in the complex multistage process of cancer metastasis, we examined galectin-3 and galectin-3-binding site expression in a series of 82 spontaneous canine mammary tumors (CMT) and two CMT cell lines. Benign CMT tumors exhibited strong nuclear/cytoplasmic galectin-3 immunostaining, whereas malignant CMT tumors and metastases exhibited dramatically decreased galectin-3 expression with the majority of the immunostaining confined to the cytoplasm. Interestingly, intravascular tumor cells overexpressed galectin-3 regardless of their location. CMT-U27 xenografts displayed the same pattern of galectin-3 expression found in spontaneous malignant CMT. In parallel with the downregulation of galectin-3, malignant CMT displayed an overall loss of galectin-3-binding sites in the ECM and focal expression of galectin-3-binding sites mainly detected in intravascular tumor cells and endothelium. Furthermore, loss of galectin-3-binding sites was correlated with the downregulation of GLT25D1, a beta (1-O) galactosyltransferase that modifies collagen, and upregulation of stromal galectin-1. Finally, GLT25D1 mRNA expression was strikingly downregulated in malignant CMT-U27 compared with the benign cell line, and its expression was further de-creased in a galectin-3 knockdown CMT-U27 cell line. We therefore hypothesized that the loss of galectin-3-binding sites in the ECM in conjunction with the overexpression of galectin-3 in specific tumor cell subpopulations are crucial events for the development of mammary tumor metastases.

Fundacao para a Ciencia e a Tecnologia (FCT), Programa Operacional Ciencia e Inovacao 2010 (POCI 2010) do Quadro Comunitario de Apoio III[PTDC/CVT/655337/2006]

FCT, the Portuguese Foundation for Science and Technology

Identificador

GLYCOBIOLOGY, v.20, n.11, p.1341-1352, 2010

0959-6658

http://producao.usp.br/handle/BDPI/21887

10.1093/glycob/cwq103

http://dx.doi.org/10.1093/glycob/cwq103

Idioma(s)

eng

Publicador

OXFORD UNIV PRESS INC

Relação

Glycobiology

Direitos

restrictedAccess

Copyright OXFORD UNIV PRESS INC

Palavras-Chave #extracellular matrix #galectin-3 #galectin-3-binding sites #metastasis #tumor stroma #BREAST EPITHELIAL-CELLS #CARCINOMA-CELLS #PROSTATE-CANCER #DIFFERENTIAL EXPRESSION #CYTOPLASMIC GALECTIN-3 #DECREASED EXPRESSION #CYCLE ARREST #E-CADHERIN #ADHESION #PROGRESSION #Biochemistry & Molecular Biology
Tipo

article

original article

publishedVersion